Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Medroxyprogesterone acetate

Summary

Persistence. It cannot be excluded that medroxyprogesterone acetate is persistent, due to the lack of data.
Bioaccumulation. It cannot be excluded that medroxyprogesterone acetate bioaccumulates, due to the lack of data.
Toxicity. It cannot be excluded that medroxyprogesterone acetate is toxic, due to the lack of data.
Risk. Medroxyprogesterone has a low environmental risk compared to other progestogens and is a good alternative for hormonal contraception from an environmental point of view. This method has a lower environmental risk than all combination products (estrogen + progestogen) and is comparable to the low environmental risk associated with the use of drospirenone as an intermediate-dose progestogen method.

 

Environmental information is missing on fass.se for medroxyprogesterone acetate (2025-04-15). The risk comes from the report from Goodpoint.

Detailede information

Report Goodpoint 2024

The report from Goodpoint 2024 aims to present an overall, comparative assessment for the treatment options recommended for all indications under the therapeutic area of ​​gynecology and obstetrics in the 2024 Wise list (the formulary for Region Stockholm, Sweden) containing either estrogens or progestogens + estetrol. The risk assessment does not aim to assess absolute or quantitative risk (which, for example, strongly depends on dilution in different recipients) but is primarily of a comparative nature, i.e., a ranking of the risk between different treatment options. For more information see the report.

Author: Health and Medical Care Administration, Region Stockholm